However, although hyperglycemia may have a negative impact on prognosis in hospitalized patients with COVID-1944, it seems that the effect on glucose control would not be the only responsible for the beneficial effect of DPP-4 inhibitors in patients with COVID-19, since we saw the improvements in glucose levels during the first 24 h of hospitalization and the need of mechanical ventilation was between 4–5 days. The gene discussed is DPP4; the disease is Hyperglycemia.